U.S. markets open in 35 minutes
  • S&P Futures

    4,589.75
    +14.00 (+0.31%)
     
  • Dow Futures

    34,688.00
    +66.00 (+0.19%)
     
  • Nasdaq Futures

    16,067.50
    +79.00 (+0.49%)
     
  • Russell 2000 Futures

    2,213.80
    +8.60 (+0.39%)
     
  • Crude Oil

    68.52
    +2.02 (+3.04%)
     
  • Gold

    1,774.10
    +11.40 (+0.65%)
     
  • Silver

    22.44
    +0.13 (+0.58%)
     
  • EUR/USD

    1.1303
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.4290
    -0.0190 (-1.31%)
     
  • Vix

    26.19
    -4.93 (-15.84%)
     
  • GBP/USD

    1.3279
    -0.0023 (-0.18%)
     
  • USD/JPY

    113.3650
    +0.1560 (+0.14%)
     
  • BTC-USD

    56,944.75
    +659.53 (+1.17%)
     
  • CMC Crypto 200

    1,453.85
    +14.96 (+1.04%)
     
  • FTSE 100

    7,158.11
    +28.90 (+0.41%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     

Savara to Participate in Two Upcoming Investor Healthcare Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

H.C. Wainwright 23rd Annual Global Investment Conference

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

AUSTIN, Texas, September 07, 2021--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the following healthcare conferences:

  • H.C. Wainwright 23rd Annual Global Investment Conference: A pre-recorded webcast of the presentation will be available beginning at 7:00 AM ET / 4:00 AM PT on September 13, 2021.

  • Oppenheimer Fall Healthcare Life Sciences & MedTech Summit: A live webcast of the presentation will take place at 12:25 PM ET / 9:25 AM PT on September 20, 2021.

Both webcast presentations will be available through the Investors page of Savara’s website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization.

More information can be found at https://savarapharma.com/. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005242/en/

Contacts

Savara Inc. IR & PR
Anne Erickson (anne.erickson@savarapharma.com)
(512) 851-1366